Kessler Foundation   Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: East Hanover NJ United States (1985)

Organization Overview

First Clinical Trial
2003
NCT00871455
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Kessler Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aphasia (Phase 1)

Autonomic Dysreflexia (Phase 2)

Brain Injuries (Phase 4)

Brain Injuries, Traumatic (Phase 4)

Dementia (Phase 1)

Dementia, Vascular (Phase 1)

Fatigue (Phase 2)

Hypotension (Phase 2)

Memory Disorders (Phase 1)

Multiple Sclerosis (Phase 2)

Rotator Cuff Injuries (Phase 2)

Sclerosis (Phase 2)

Shoulder Impingement Syndrome (Phase 1)

Shoulder Pain (Phase 2)

Spinal Cord Injuries (Phase 3)

Stroke (Phase 1)

Syndrome (Phase 1)

Tendinopathy (Phase 2)

Urinary Bladder, Neurogenic (Phase 2)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 18